Complete Genomics Details Low-Cost Sequencing Tech in Paper; Collaborators Encouraged by Results

"What's impressive is that they really have quite good coverage for outstanding quality, and that is what will allow this technology to catch people's attention," according to Pfizer's David Cox, one of the company's early-access customers.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.